ACS Nano,
Journal Year:
2025,
Volume and Issue:
19(5), P. 5376 - 5391
Published: Jan. 31, 2025
In
situ
vaccination
is
considered
a
promising
cancer
immunotherapy
strategy
to
elicit
tumor-specific
T
cell
response.
Live
bacteria
effectively
enhanced
the
immune
response
in
irradiated
tumors
as
it
can
activate
multiple
cells.
However,
adaptive
remains
low
since
lack
efficient
delivery
of
antigen
dendritic
cells
(DCs).
Here,
we
show
that
tumor
antigens
be
metabolically
labeled
with
azido
groups
situ,
allowing
for
their
specific
capture
by
orthogonally
engineered
Salmonella
via
bioorthogonal
chemistry.
Subsequently,
these
are
efficiently
delivered
DCs
through
active
movement
bacteria.
Intratumorally
injected
captured
and
improved
presentation
DCs.
This
increased
proportion
antigen-specific
CD8+
tumors,
further
resulting
systemic
antitumor
effects
bilateral
melanoma
mouse
model.
The
were
abrogated
Batf3-/-
mice
or
after
depletion,
indicating
dependent
on
responses.
Overall,
our
work
presents
combining
bacterial
engineering
labeling,
which
may
guide
development
vaccines
future.
Cell Systems,
Journal Year:
2025,
Volume and Issue:
16(2), P. 101169 - 101169
Published: Feb. 1, 2025
Bacteria
represent
a
promising
dynamic
delivery
system
for
the
treatment
of
disease.
In
skin,
relevant
location
Cutibacterium
acnes
within
hair
follicle
makes
this
bacterium
an
attractive
chassis
dermal
biotechnological
applications.
Here,
we
provide
genetic
toolbox
engineering
traditionally
intractable
bacterium,
including
basic
gene
expression
tools,
biocontainment
strategies,
markerless
engineering,
and
transcriptional
regulation.
As
proof
concept,
develop
antioxidant-secreting
strain
capable
reducing
oxidative
stress
in
UV
model.
Cancer Biology & Therapy,
Journal Year:
2023,
Volume and Issue:
24(1)
Published: July 27, 2023
Recent
evidence
has
shown
that
the
human
microbiome
is
associated
with
various
diseases,
including
cancer.
The
salivary
microbiome,
fecal
and
circulating
microbial
DNA
in
blood
plasma
have
all
been
used
experimentally
as
diagnostic
biomarkers
for
many
types
of
microbiomes
present
within
local
tissue,
other
regions,
tumors
themselves
to
promote
restrict
development
progression
cancer,
most
often
by
affecting
cancer
cells
or
host
immune
system.
These
microbes
also
impact
efficacy
therapies,
radiation,
chemotherapy,
immunotherapy.
Here,
we
review
research
advances
focused
on
how
these
different
facets
why
they
are
important
clinical
care
It
only
better
understanding
roles
play
diagnosis,
development,
progression,
treatment
will
be
able
catch
treat
early.
Cancer Cell,
Journal Year:
2023,
Volume and Issue:
42(1), P. 16 - 34
Published: Dec. 28, 2023
Over
the
last
decade,
composition
of
gut
microbiota
has
been
found
to
correlate
with
outcomes
cancer
patients
treated
immunotherapy.
Accumulating
evidence
points
various
mechanisms
by
which
intestinal
bacteria
act
on
distal
tumors
and
how
harness
this
complex
ecosystem
circumvent
primary
resistance
immune
checkpoint
inhibitors.
Here,
we
review
state
field
in
context
melanoma,
recent
breakthroughs
defining
microbial
modes
action,
modulate
enhance
response
The
host-microbe
interaction
may
be
deciphered
use
"omics"
technologies,
will
guide
patient
stratification
development
microbiota-centered
interventions.
Efforts
needed
advance
current
gaps
knowledge
are
also
discussed.
Protein & Cell,
Journal Year:
2023,
Volume and Issue:
15(4), P. 239 - 260
Published: Nov. 8, 2023
Abstract
The
profound
influence
of
microbiota
in
cancer
initiation
and
progression
has
been
under
the
spotlight
for
years,
leading
to
numerous
researches
on
microbiome
entering
clinical
evaluation.
As
promising
biomarkers
therapeutic
targets,
critical
involvement
practice
increasingly
appreciated.
Here,
recent
progress
this
field
is
reviewed.
We
describe
potential
tumor-associated
as
effective
diagnostic
prognostic
biomarkers,
respectively.
In
addition,
we
highlight
relationship
between
efficacy,
toxicity,
or
side
effects
commonly
utilized
treatments
cancer,
including
chemotherapy,
radiotherapy,
immunotherapy.
Given
that
microbial
factors
treatment
outcome,
further
summarize
some
dominating
interventions
discuss
hidden
risks
these
strategies.
This
review
aims
provide
an
overview
applications
advancements
microbes
relevance.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: June 26, 2024
Glioblastoma
(GBM)
tumors
are
the
most
aggressive
primary
brain
in
adults
that,
despite
maximum
treatment,
carry
a
dismal
prognosis.
GBM
exhibit
tissue
hypoxia,
which
promotes
tumor
aggressiveness
and
maintenance
of
glioma
stem
cells
creates
an
overall
immunosuppressive
landscape.
This
article
reviews
how
hypoxic
conditions
overlap
with
inflammatory
responses,
favoring
proliferation
inhibiting
cytotoxic
T
cell
development.
Immunotherapies,
including
vaccines,
immune
checkpoint
inhibitors,
CAR-T
therapy,
represent
promising
avenues
for
treatment.
However,
challenges
such
as
heterogeneity,
TME,
BBB
restrictiveness
hinder
their
effectiveness.
Strategies
to
address
these
challenges,
combination
therapies
targeting
actively
being
explored
improve
outcomes
patients.
Targeting
hypoxia
immunotherapy
represents
potential
strategy
enhance
treatment
efficacy.
Current Opinion in Biotechnology,
Journal Year:
2024,
Volume and Issue:
85, P. 103061 - 103061
Published: Jan. 13, 2024
Bacterial
therapeutics
have
emerged
as
promising
delivery
systems
to
target
tumors.
These
engineered
live
can
be
harnessed
modulate
the
tumor
microenvironment
or
deliver
and
selectively
release
therapeutic
payloads
A
major
challenge
is
bacteria
systemically
without
causing
widespread
inflammation,
which
critical
for
many
tumors
that
are
not
accessible
direct
intratumoral
injection.
We
describe
potential
strategies
address
this
challenge,
along
with
approaches
specific
payload
biocontainment
ensure
safety.
will
pave
way
development
of
cost-effective,
widely
applicable
next-generation
cancer
therapeutics.
